Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

MyNCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1965 1
1978 4
1979 23
1980 10
1981 11
1982 2
1983 7
1984 11
1985 8
1987 3
1988 1
1989 5
1990 3
1991 3
1992 5
1993 5
1994 6
1995 5
1996 4
1997 5
1998 5
1999 5
2000 6
2001 14
2002 10
2003 7
2004 6
2005 8
2006 8
2007 6
2008 12
2009 11
2010 13
2011 13
2012 22
2013 15
2014 13
2015 20
2016 16
2017 14
2018 15
2019 2
2020 0
Text availability
Article attribute
Article type
Publication date

Search Results

328 results
Results by year
Filters applied: . Clear all
Page 1
Mycosis Fungoides and Sezary Syndrome.
Foss FM and Girardi M. Hematol Oncol Clin North Am 2017 - Review. PMID 28340880
Mycosis fungoides and the Sezary syndrome (SS) are rare lymphomas of CD4(+) helper T cells. There is stagewise progression from patch/plaques to thicker tumor lesions/diffuse erythroderma. ...
Mycosis fungoides and the Sezary syndrome (SS) are rare lymphomas of CD4(+) helper T cells. There is stagewise progression fro …
The mutational landscape of cutaneous T cell lymphoma and Sézary syndrome.
da Silva Almeida AC, et al. Nat Genet 2015. PMID 26551667 Free PMC article.
Sézary syndrome is a leukemic and aggressive form of cutaneous T cell lymphoma (CTCL) resulting from the malignant transformation of skin-homing central memory CD4(+) T cells. Here we performed whole-exome sequencing of tumor-normal sample pairs from 25 patients with Sézary syndrome and 17 patients with other CTCLs. ...
Sézary syndrome is a leukemic and aggressive form of cutaneous T cell lymphoma (CTCL) resulting from the malignant transformation of …
Blood classification and blood response criteria in mycosis fungoides and Sézary syndrome using flow cytometry: recommendations from the EORTC cutaneous lymphoma task force.
Scarisbrick JJ, et al. Eur J Cancer 2018 - Review. PMID 29477101 Free article.
Our current mycosis fungoides (MF) and Sézary Syndrome (SS) staging system includes blood-classification from B0-B2 for patch/plaque/tumour or erythroderma based on manual Sézary counts but results from our EORTC survey confirm these are rarely performed in patch/plaque/tumour MF, and there is a trend towards using flow cytometry to measure blood-class. ...Studies have not shown a statistically worse difference in prognosis in erythrodermic MF patients with low-level blood involvement (IIIB) versus those without (IIIA), but Sezary patients who by definition have a leukaemic blood picture (staged IVA1 or higher) have a worse prognosis. ...
Our current mycosis fungoides (MF) and Sézary Syndrome (SS) staging system includes blood-classification from B0-B2 for patch/plaque/ …
Clinical end points and response criteria in mycosis fungoides and Sézary syndrome: a consensus statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer.
Olsen EA, et al. J Clin Oncol 2011. PMID 21576639 Free PMC article.
Mycosis fungoides (MF) and Sézary syndrome (SS), the major forms of cutaneous T-cell lymphoma, have unique characteristics that distinguish them from other types of non-Hodgkin's lymphomas. ...
Mycosis fungoides (MF) and Sézary syndrome (SS), the major forms of cutaneous T-cell lymphoma, have unique characteristics that disti …
Therapeutic and prognostic significance of PARP-1 in advanced mycosis fungoides and Sezary syndrome.
Lemchak D, et al. Exp Dermatol 2018. PMID 29205518 Free PMC article.
In conclusion, we believe that PARP-1 may serve not only as a biomarker at initial biopsies for a disease that may become aggressive but also as a new therapeutic target of advanced MF and Sézary syndrome....
In conclusion, we believe that PARP-1 may serve not only as a biomarker at initial biopsies for a disease that may become aggressive but als …
Single-cell heterogeneity in Sézary syndrome.
Buus TB, et al. Blood Adv 2018. PMID 30139925 Free PMC article.
Sézary syndrome (SS) is an aggressive leukemic variant of cutaneous T-cell lymphoma (CTCL) with a median life expectancy of less than 4 years. ...
Sézary syndrome (SS) is an aggressive leukemic variant of cutaneous T-cell lymphoma (CTCL) with a median life expectancy of less than …
Tumor microenvironment in mycosis fungoides and Sézary syndrome.
Rubio Gonzalez B, et al. Curr Opin Oncol 2016 - Review. PMID 26632770
PURPOSE OF REVIEW: Mycosis fungoides and Sézary syndrome arise from malignant T cells that reside in skin, and subsequently are capable of circulating between skin, lymph nodes, and blood. ...RECENT FINDINGS: Recent studies have discovered that malignant T cells in Sézary syndrome are of the central memory T-cell subset, whereas those in mycosis fungoides are nonrecirculating skin-resident effector memory T cells, and have shown a protumorigenic role of mast cells and macrophages in CTCL. ...
PURPOSE OF REVIEW: Mycosis fungoides and Sézary syndrome arise from malignant T cells that reside in skin, and subsequently are capab …
Sezary syndrome: diagnosis and management.
Ogilvie C, et al. J R Coll Physicians Edinb 2012. PMID 23240118
We describe a case of a delayed diagnosis of Sezary syndrome in a patient with longstanding generalised pruritus, erythroderma, alopecia and nail dystrophy. ...
We describe a case of a delayed diagnosis of Sezary syndrome in a patient with longstanding generalised pruritus, erythroderma …
Novel phosphorylated TAK1 species with functional impact on NF-κB and β-catenin signaling in human Cutaneous T-cell lymphoma
Gallardo F, et al. Leukemia 2018. PMID 29511289 Free PMC article.
Cutaneous T-cell lymphomas (CTCLs) represent different subtypes of lymphoproliferative disorders with no curative therapies for the advanced forms of the disease (namely mycosis fungoides and the leukemic variant, Sézary syndrome). ...Inhibition of TAK1 precluded NF-κB and β-catenin signaling and induced apoptosis of CTCL cell lines and primary Sézary syndrome cells both in vitro and in vivo. ...
Cutaneous T-cell lymphomas (CTCLs) represent different subtypes of lymphoproliferative disorders with no curative therapies for the advanced …
328 results
Jump to page
Feedback